Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX516 in elderly participants with mild cognitive impairment
NCT00040443Phase 2Completed
- Sponsor
- RespireRx Pharmaceuticals
- Start
- Apr 2002
- Primary completion
- Aug 2003
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cx516 in Mild Cognitive Impairment (MCI), sponsored by RespireRx Pharmaceuticals. Started Apr 2002; status: completed.
02
Drugs
cx516
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00040443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040443.